ProCE Banner Activity

Answering Key Clinical Questions in Personalizing Treatment for Patients With Metastatic Prostate Cancer

Clinical Thought

Xin Gao, MD, provides his perspective on key questions from a live meeting on management of patients with metastatic prostate cancer, including personalizing therapy for castration-sensitive prostate cancer, use of PARP inhibitors for patients with BRCA1/2 mutations, and optimizing the use of PSMA-targeted therapies in clinical practice.

Released: July 26, 2023

Share

Faculty

Xin Gao

Xin Gao, MD

Assistant Professor of Medicine
Harvard Medical School
Medical Oncologist
Medicine-Hematology/Oncoloy
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck Sharp & Dohme Corp., and Novartis Pharmaceuticals Corporation.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Xin Gao, MD

Assistant Professor of Medicine
Harvard Medical School
Medical Oncologist
Medicine-Hematology/Oncoloy
Massachusetts General Hospital
Boston, Massachusetts

Xin Gao, MD: consultant/advisor/speaker: Bayer, Flare, Guardant, Myovant, PathAI, PureTech Health, Silverback.